IASLC Atlas of PD-L1 Testing in Lung Cancer

Overview

The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a new resource for understanding programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays. It is designed to help pathologists, clinicians, other health care personnel and patients better understand emerging programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays.

Date
Nov 09, 2017 -
Nov 09, 2017
Location

Online

After viewing this program attendees will:

  • Recognize the selection and use of IHC testing;
  • Employ the Atlas of P-L1 IHC Testing as a resource for diagnosis and treatment options;
  • Identify the changing landscape of laboratory testing and current information about emerging PD-L1 assays.

Ming-Sound Tsao, MD, FRCPC
Senior Scientist, Princess Margaret Cancer Center\Professor of Laboratory Medicine and Pathology, M. Qasim Choski Chair in Lung Cancer Translational Research, University of Toronto, Canada.

For any inquiries, please contact [email protected].

After viewing this program attendees will:

  • Recognize the selection and use of IHC testing;
  • Employ the Atlas of P-L1 IHC Testing as a resource for diagnosis and treatment options;
  • Identify the changing landscape of laboratory testing and current information about emerging PD-L1 assays.

Ming-Sound Tsao, MD, FRCPC
Senior Scientist, Princess Margaret Cancer Center\Professor of Laboratory Medicine and Pathology, M. Qasim Choski Chair in Lung Cancer Translational Research, University of Toronto, Canada.

For any inquiries, please contact [email protected].

Share

Interested in advertising and exhibit opportunities?